FDA
approval
· 2022-01-31
FDA Approved: IRBESARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
Summary
FDA approved a supplemental application for Teva's IRBESARTAN AND HYDROCHLOROTHIAZIDE, establishing approval of the generic combination product for hypertension…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for IRBESARTAN AND HYDROCHLOROTHIAZIDE (IRBESARTAN AND HYDROCHLOROTHIAZIDE)